Share

Novartis AG (NOVN.SIX) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 12 April 2026Deep analysis 12 April 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

11 AI Advisor Reports

Select an advisor report.

Superintelligence AI

The Anthropologist FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+77.4%

Includes 2.09% annual net dividend contribution

1. Investment Thesis — Base Case

The most reasonable path over the next five years is a classic 'valley and ascent' trajectory. In the near term (2026), Novartis will absorb the mechanical damage of the Entresto patent expiration and the accounting costs of integrating Avidity. Price appreciation will be muted, supported primarily by safe-haven capital flows and aggressive share buybacks rather than explosive earnings growth. However, by 2027, the underlying physics of their strategic shift will take over. The pure-play structure will allow high-margin products like Kisqali and Pluvicto to exert their outsized influence on the bottom line. Key assumptions driving this trajectory:

The Entresto generic erosion occurs predictably, but is fully offset by new product scaling by late 2027.
The Avidity acquisition successfully matures, giving Novartis a defensible RNA technology platform.
US pricing pressure compresses margins slightly, but global volume demand compensates.
AI-driven discovery shortens the R&D cycle, improving capital efficiency.
The CHF 10 billion buyback mathematically floors the stock against severe drawdowns.

Ultimately, Novartis will successfully transition its portfolio, returning to >40% core margins by 2028-2029. The implied market capitalization remains entirely realistic given the aging global demographic and the expanding pool of global liquidity seeking low-volatility returns. This is a civilizational compounding machine successfully executing a required upgrade.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in CHF.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (CHF)
Observed price	2021-04-08	76.4
Observed price	2021-04-20	76.9
Observed price	2021-05-02	74.4
Observed price	2021-05-10	74.9
Observed price	2021-05-14	76.3
Observed price	2021-06-03	76.3
Observed price	2021-06-19	81.3
Observed price	2021-07-13	80.7
Observed price	2021-07-21	79.2
Observed price	2021-08-02	79.2
Observed price	2021-08-14	81.7
Observed price	2021-08-30	80.2
Observed price	2021-09-19	73.3
Observed price	2021-09-23	72.8
Observed price	2021-10-05	72.0
Observed price	2021-10-25	73.7
Observed price	2021-11-10	72.1
Observed price	2021-11-22	72.8
Observed price	2021-12-04	70.0
Observed price	2021-12-16	73.4
Observed price	2022-01-09	77.9
Observed price	2022-01-17	77.9
Observed price	2022-01-25	73.4
Observed price	2022-02-26	76.6
Observed price	2022-03-06	73.5
Observed price	2022-03-10	72.6
Observed price	2022-04-03	77.4
Observed price	2022-04-07	80.9
Observed price	2022-04-15	82.6
Observed price	2022-05-09	79.7
Observed price	2022-05-25	82.9
Observed price	2022-06-06	81.4
Observed price	2022-06-22	74.4
Observed price	2022-06-30	76.5
Observed price	2022-07-20	78.8
Observed price	2022-08-09	78.9
Observed price	2022-08-13	76.5
Observed price	2022-08-25	76.0
Observed price	2022-09-18	73.2
Observed price	2022-09-26	70.1
Observed price	2022-10-04	73.0
Observed price	2022-10-20	72.2
Observed price	2022-11-09	77.5
Observed price	2022-11-17	75.0
Observed price	2022-12-07	81.3
Observed price	2022-12-31	79.6
Observed price	2023-01-04	81.3
Observed price	2023-01-16	81.7
Observed price	2023-02-05	75.3
Observed price	2023-02-21	76.5
Observed price	2023-03-01	74.5
Observed price	2023-03-13	70.8
Observed price	2023-04-02	79.9
Observed price	2023-04-10	82.3
Observed price	2023-04-30	86.9
Observed price	2023-05-08	88.5
Observed price	2023-05-28	83.6
Observed price	2023-06-01	83.7
Observed price	2023-06-17	86.0
Observed price	2023-07-11	81.0
Observed price	2023-07-23	86.1
Observed price	2023-08-04	84.4
Observed price	2023-08-12	86.0
Observed price	2023-09-05	83.2
Observed price	2023-09-17	87.3
Observed price	2023-10-03	87.1
Observed price	2023-10-11	89.7
Observed price	2023-10-27	83.8
Observed price	2023-11-08	84.9
Observed price	2023-11-16	83.2
Observed price	2023-11-24	86.8
Observed price	2023-12-26	84.3
Observed price	2024-01-07	90.8
Observed price	2024-01-19	93.8
Observed price	2024-01-31	89.4
Observed price	2024-02-12	87.7
Observed price	2024-02-24	91.0
Observed price	2024-03-11	88.8
Observed price	2024-03-19	85.5
Observed price	2024-04-16	85.0
Observed price	2024-04-28	89.3
Observed price	2024-05-02	88.3
Observed price	2024-05-14	93.5
Observed price	2024-05-30	91.8
Observed price	2024-06-23	95.6
Observed price	2024-07-13	99.8
Observed price	2024-07-21	96.0
Observed price	2024-08-06	93.3
Observed price	2024-08-18	99.9
Observed price	2024-08-30	102
Observed price	2024-09-11	97.5
Observed price	2024-10-01	96.8
Observed price	2024-10-13	100
Observed price	2024-10-17	101
Observed price	2024-11-10	92.6
Observed price	2024-11-22	93.7
Observed price	2024-12-08	89.3
Observed price	2024-12-20	86.7
Observed price	2025-01-05	89.7
Observed price	2025-01-17	89.3
Observed price	2025-02-02	95.6
Observed price	2025-02-14	95.4
Observed price	2025-03-02	98.5
Observed price	2025-03-10	101
Observed price	2025-03-14	96.3
Observed price	2025-04-03	97.3
Observed price	2025-04-11	86.1
Observed price	2025-05-01	94.2
Observed price	2025-05-13	90.5
Observed price	2025-05-29	93.2
Observed price	2025-06-06	97.1
Observed price	2025-07-08	97.6
Observed price	2025-07-20	92.0
Observed price	2025-07-24	93.0
Observed price	2025-08-17	100
Observed price	2025-09-06	103
Observed price	2025-09-14	97.9
Observed price	2025-09-18	96.7
Observed price	2025-10-08	107
Observed price	2025-10-16	104
Observed price	2025-10-28	98.9
Observed price	2025-11-21	103
Observed price	2025-12-03	107
Observed price	2025-12-11	106
Observed price	2026-01-04	111
Observed price	2026-01-08	114
Observed price	2026-02-01	116
Observed price	2026-02-05	119
Observed price	2026-02-25	130
Observed price	2026-03-09	125
Observed price	2026-03-21	117
Observed price	2026-04-02	123
Observed price	2026-04-26	114
Observed price	2026-05-08	113
Observed price	2026-05-24	120
Observed price	2026-06-01	114
Observed price	2026-06-13	121
Observed price	2026-07-03	128
Observed price	2026-07-15	122
Observed price	2026-07-27	129
Observed price	2026-08-16	123
Observed price	2026-09-01	131
Observed price	2026-09-09	112
Observed price	2026-09-15	114
Observed price	2026-09-17	116
Observed price	2026-09-18	115
Published advisor forecast	2026-04-10	122
Published advisor forecast	2026-07-10	119
Published advisor forecast	2026-10-10	118
Published advisor forecast	2027-01-10	123
Published advisor forecast	2027-04-10	129
Published advisor forecast	2027-07-10	132
Published advisor forecast	2027-10-10	136
Published advisor forecast	2028-01-10	141
Published advisor forecast	2028-04-10	145
Published advisor forecast	2028-07-10	148
Published advisor forecast	2028-10-10	154
Published advisor forecast	2029-01-10	162
Published advisor forecast	2029-04-10	167
Published advisor forecast	2029-07-10	170
Published advisor forecast	2029-10-10	175
Published advisor forecast	2030-01-10	170
Published advisor forecast	2030-04-10	173
Published advisor forecast	2030-07-10	178
Published advisor forecast	2030-10-10	182
Published advisor forecast	2031-01-10	189
Published advisor forecast	2031-04-10	195

2. Scenarios & Signals

Bull case

What happens if the biological breakthroughs arrive ahead of schedule? In the bull case, Novartis's radioligand therapies achieve total dominance in early-stage cancer treatments, and the Avidity RNA platform delivers a functional cure for a major disease.

The patent cliff is completely overwhelmed by unexpected upside in new drug approvals.
AI integration drops R&D costs by 20%, structurally elevating margins to 45%.
Deep global stagflation forces institutional capital to crowd into defensive pharma, expanding the P/E multiple dramatically.
The company becomes the undisputed apex node of programmable biology.

Bear case

What if the programmed entropy of the industry outpaces the company's ability to innovate? In the bear case, the pipeline fails to deliver.

Late-stage trials for crucial oncology and immunology replacements fail to meet primary endpoints.
of Entresto and Tasigna occurs faster than modeled, collapsing near-term cash flows.
US populist policies escalate into forced patent stripping, destroying international pricing power.
The Avidity acquisition is written down as a costly failure, leaving the company structurally impaired.

Current crowd narrative

The noisy market currently views Novartis through a lens of cautious ambivalence. The consensus treats the 2025-2026 loss of exclusivity for the blockbuster drug Entresto as a massive, unavoidable sinkhole that will swallow earnings growth. Analysts point to the guided margin dilution from the Avidity acquisition and frame 2026 as a 'lost year' of transition. The anchoring bias is historical: whenever major pharma faces a , the crowd assumes dead money until the next blockbuster is undeniably proven. They see a safe, boring dividend payer temporarily stuck in an earnings trough.

Alpha-gap assessment

The crowd is fixated on the entropy of the past (expiring patents) while systematically ignoring the negentropy of the present (structural efficiency). By shedding its generic business and aggressively integrating AI into discovery, Novartis has fundamentally altered its speed of value creation. The market misprices the reality that a 40% margin pure-play entity generates enough cash to simply buy its way out of the patent valley. Furthermore, in a chaotic geopolitical regime defined by war and stagflation, the crowd is underestimating the premium civilizational capital will assign to deep, inelastic biological demand.

Convergence catalyst

The convergence will be triggered by the mid-2027 clinical data readouts. When Novartis demonstrates that its next-generation oncology and RNA pipelines are producing viable blockbusters faster than is destroying legacy revenue, the market will be forced to abandon the '' penalty and reprice the stock as a compounded growth engine.

Macro-regime alignment

The current macro regime is highly favorable. In a world characterized by fractured supply chains, energy shocks (Hormuz closure), and volatile fiat credibility (the Warsh Shock), global capital frantically searches for safe yield. A Swiss-domiciled company selling non-discretionary survival tools (oncology, cardiology medicines) provides near-perfect shelter from geopolitical chaos. The macro wind is firmly at its back.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.2
Expected volatility regime: low_steady
Convergence-cycle position: early_discovery

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
NEXT Generation Oncology Scaling	Why do we value a chemical structure? Because it delays human entropy. Novartis is rapidly scaling high-margin, life-extending therapies like Kisqali and Pluvicto, which recently surged in sales by 57% and 42% respectively [1.4]. Does this growth simply replace older drugs, or does it expand the company's total extraction of value? By targeting specific cancer cells with radioactive precision (radioligand therapy), Novartis commands premium pricing. This scaling is a negentropy engine, converting proprietary science into durable cash flow that will easily outpace the decay of older product lines over our 5-year horizon.	Not available%	+12.0%
Biological Haven Demand	What happens when global supply chains fracture and energy costs spike? Discretionary spending collapses, but the human biological imperative to survive remains absolute. In a world currently traumatized by the Middle East energy shock and stagflation, capital seeks safety. A pharmaceutical giant based in Switzerland producing non-negotiable health interventions acts as a civilizational safe harbor. Investors will pay a premium for this biological anchoring, treating the stock as a proxy for a high-yield, low-risk sovereign bond.	Not available%	+8.0%
AI Accelerated Discovery Pipeline	How does a company survive the programmed obsolescence of its patents? By accelerating the rate at which it invents. Novartis is deeply embedding Artificial Intelligence into its drug discovery processes, utilizing generative models to predict molecular interactions and reduce the failure rate of early-stage trials. By shortening the time it takes to move from a biological target to a functional drug, the company increases its thermodynamic efficiency, requiring less capital and time to generate new, patent-protected revenue streams.	Not available%	+7.0%
RNA Platform Expansion	Is a drug merely a chemical, or is it a software patch for the human body? With the acquisition of Avidity, which closes in the first half of 2026, Novartis is expanding its footprint in RNA therapeutics. This represents a shift toward programmable genetic medicines. While it dilutes margins slightly today, it aligns perfectly with the civilizational trajectory of viewing biology as an editable code. This platform will yield entirely new classes of therapies within the forecast horizon.	Not available%	+6.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE Entresto Patent Cliff	What happens when intellectual property rights evaporate? The physics of the pharmaceutical market dictate that generic competition floods in, driving prices to near-zero marginal cost. Novartis's heart failure drug, Entresto, which generated roughly USD 7.8 billion in 2024, is actively losing exclusivity [1.1]. This programmed revenue destruction is the heaviest thermodynamic drag on the company. The company must run faster just to stand still as generic alternatives erode its most profitable historical foundation.	Not available%	-10.0%
Populist US Pricing Controls	How does a civilizational system resolve the tension between corporate profit and population health? Often through state intervention. The new US administration's 'TrumpRx' initiative and ongoing Medicare price negotiations directly threaten the pricing power of foreign pharmaceutical companies. When the state mandates lower prices, the gross margin of the enterprise compresses. This political friction will act as a persistent headwind against Novartis's ability to maximize revenue in the world's most lucrative healthcare market.	Not available%	-8.0%
Avidity Integration Margin Dilution	Does acquiring the future come with a cost today? Yes. The debt-funded acquisition of Avidity brings increased research and development burdens. Management has explicitly guided that this will cause a 1 to 2 percentage point dilution to core operating margins in 2026. This short-term mechanical drag on profitability gives the noisy market an excuse to discount the stock in the near term, even if the long-term biological logic is sound.	Not available%	-4.0%
Swiss Franc Currency Headwinds	What is the penalty for being based in a safe-haven country? Your currency becomes too strong. As global capital flees geopolitical chaos into the Swiss Franc, Novartis faces an accounting friction. It earns revenue in depreciating global currencies (like the Euro and Dollar) but reports its baseline in CHF. This translation effect mechanically shrinks reported top-line growth, obscuring the true volume of biological demand the company is fulfilling.	Not available%	-3.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Radioligand Platform Monopoly	What if a company builds a therapeutic infrastructure so complex that competitors simply cannot replicate it? Radioligand therapies require radioactive isotopes to be manufactured and injected into patients within strict half-life windows. If Novartis establishes an unbreakable logistical monopoly in this space, capturing multiple new cancer indications, it transforms a moderate competitive advantage into an impenetrable civilizational moat, driving massive upward earnings revisions.	35.0%	+14.0%
RNA Efficacy Breakthrough	What happens if a new technology moves from treating symptoms to reprogramming the disease? If the newly acquired Avidity RNA platform delivers clinical trial data demonstrating a functional cure for a major neuromuscular or cardiovascular disease, the market will abruptly reprice Novartis from a 'steady pharmaceutical' to a 'genetic disruption' platform. This single data readout could instantly bridge the revenue gap left by expiring legacy patents.	25.0%	+12.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Hostile US IP Stripping	What happens if a populist government weaponizes intellectual property? Under the guise of national security or healthcare emergency, the US administration could move beyond simple price negotiations and utilize 'march-in rights' or forced generic licensing for high-cost foreign pharmaceuticals. If Novartis's patents are effectively voided by state decree before their natural expiration, the core thermodynamic engine of the company would stall.	15.0%	-18.0%
LATE Stage Clinical Contagion	What is the danger of relying on probability? Sometimes the dice roll cold. Novartis is heavily dependent on over 15 late-stage data readouts by 2027 to replace expiring revenue [1.2]. If two or three of the largest expected pipeline assets fail to show statistical significance in human trials, the narrative of a seamless transition shatters. The market would aggressively punish the stock as the math of the patent cliff would overwhelm the growth narrative.	20.0%	-15.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_7e343e95-42be-59e9-b099-7fbd349ff80f__sb3__20260411183236
Step	Forecast date	Step change	Projected value (CHF)	Scenario rationale
1	July 10, 2026	-2.0%	119.32	Why does the price retreat slightly? The market must digest the 10% Q1 rally. As the Avidity acquisition closes, the guided 1-2% margin dilution becomes a reality on the income statement. Furthermore, the one-year anniversary of the Entresto loss of exclusivity prompts negative headline comparisons, suppressing near-term enthusiasm.
2	October 10, 2026	-1.0%	118.13	Does uncertainty breed selling? Yes. As the US political cycle peaks and 'TrumpRx' pricing pressures dominate the news cycle, healthcare stocks face regulatory friction. The patent cliff's impact on Q3 earnings confirms the 'valley' narrative, though aggressive share buybacks prevent a deeper decline.
3	January 10, 2027	+4.0%	122.86	How does capital behave when the worst is known? It buys the dip. Having absorbed the worst of the patent cliff metrics, forward-looking investors rotate back into the stock for its safe dividend yield and impending 2027 pipeline readouts. The underlying momentum of Kisqali becomes impossible to ignore.
4	April 10, 2027	+5.0%	129.00	What is the reward for successful science? Rapid repricing. Early positive data from the heavily anticipated late-stage clinical trials confirm that Novartis's R&D engine is functional. The market officially begins to look past the patent cliff, pricing in the future RNA and radioligand growth vectors.
5	July 10, 2027	+2.0%	131.58	Can momentum sustain itself without a catalyst? Only moderately. The stock consolidates its spring gains. The pure-play margin efficiency begins to clearly manifest in the quarterly reports, proving that the Sandoz spin-off was a thermodynamic success. The volatility regime remains low and steady.
6	October 10, 2027	+3.0%	135.53	How does systemic macro stress benefit a pharma giant? By making alternative investments look dangerous. Assuming persistent global inflation and geopolitical stagnation, Novartis's predictable biological cash flows attract institutional 'widow and orphan' capital, providing a slow, steady upward drift.
7	January 10, 2028	+4.0%	140.95	What happens when a new technology platform is validated? The Avidity RNA integration begins to show tangible clinical progression. Analysts revise their long-term growth models upward, abandoning the 'stagnant giant' narrative in favor of a 'biotech innovator at scale' thesis.
8	April 10, 2028	+3.0%	145.18	Is steady state growth enough? For a massive civilizational enterprise, yes. The company approaches its target of returning to a >40% core operating margin. Pluvicto's supply chain scale-up is complete, cementing Novartis's monopoly in high-end radioligand therapies.
9	July 10, 2028	+2.0%	148.08	Why the deceleration? Summer doldrums and a lack of immediate clinical catalysts lead to a quiet quarter. The share buyback program, now nearing its completion, provides a mechanical floor, but the stock awaits the next major fundamental driver.
10	October 10, 2028	+4.0%	154.00	How does AI impact the bottom line eventually? The investments in generative chemistry and predictive trial models from 2024-2026 begin to materially reduce R&D expenditure per approved drug. The thermodynamic efficiency of the company reaches its peak, expanding margins organically.
11	January 10, 2029	+5.0%	161.70	What occurs when management's long-term promises are kept? Credibility is rewarded. Novartis officially achieves its guided 5-6% sales CAGR and 40%+ margins for the 2025-2030 window. The market responds with a multiple expansion, celebrating the successful bridging of the mid-decade patent valley.
12	April 10, 2029	+3.0%	166.55	Does success invite complacency? No, but it slows the rate of change. The stock enjoys the momentum of its established product lines. Cash flows are robust, and a new capital return program (likely another massive dividend hike or buyback) is announced to manage the excess liquidity.
13	July 10, 2029	+2.0%	169.89	Why do shadows matter? The impending 2029-2030 patent cliff for Cosentyx begins to enter the forward-looking models of institutional analysts. This prevents the stock from accelerating further, instituting a period of rational consolidation.
14	October 10, 2029	+3.0%	174.98	Can a company survive two cliffs in a decade? Yes, if the foundation is broad enough. Management proactively outlines the pipeline strategy to offset Cosentyx. The market, having seen Novartis successfully navigate the Entresto cliff, affords management the benefit of the doubt.
15	January 10, 2030	-3.0%	169.73	When does reality bite? As the actual generic erosion of Cosentyx begins, mechanical revenue destruction takes place. Algorithm-driven trading models react to the slowing top-line growth metrics, causing a predictable, albeit shallow, cyclical drawdown.
16	April 10, 2030	+2.0%	173.13	How resilient is deep biological anchoring? Extremely. The drawdown is arrested quickly as the dividend yield becomes too attractive to ignore. The core RNA and oncology platforms continue to generate massive cash, cushioning the localized blow of the immunology patent loss.
17	July 10, 2030	+3.0%	178.32	What is the next frontier? Novartis begins commercializing its next generation of AI-discovered programmable medicines. The narrative shifts from traditional small molecules and biologics to personalized, software-like genetic interventions. The civilizational trajectory alignment is absolute.
18	October 10, 2030	+2.0%	181.89	Is stability a virtue? In the 2030s, yes. As technological displacement ravages other sectors of the economy, the slow, heavily regulated, deeply vital nature of human healthcare remains a fortress. The stock acts as a low-beta wealth preserver.
19	January 10, 2031	+4.0%	189.16	How does demographic destiny play out? The global population is older, sicker, and wealthier than ever before. The sheer volume of biological demand for cardiovascular and oncological care drives structural volume growth, overcoming any lingering pricing pressures or patent headwinds.
20	April 10, 2031	+3.0%	194.84	What is the emergent synthesis at the end of the horizon? Novartis has proven itself to be a durable negentropy engine. It successfully converts human capital and compute into biological order. The stock closes the five-year window significantly higher, having reliably compounded civilizational value.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: (November 19, 2025) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Superintelligence — THINKER with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.